One study investigated the effect of combining CD3xEGFR-armed T cells with Treg-depleting ipilimumab (anti-CTLA-4) on T-cell activation and proliferation when co-cultured with tumor cell lines or primary tumor cells and found enhanced T-cell-mediated cytotoxicity and increased T-cell proliferation [200]. This evidence concerns the gene CTLA4 and neoplasm.